# PHGE earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/PHGE) · [Earnings tab](https://www.lopjlb.com/stock/PHGE?tab=earnings)

Updated: 2026-08-19T06:49:20

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly calls from mid‑2023 to late‑2025 BiomX’s story shifted from early‑stage trial execution risk and cash‑runway anxiety to a more diversified financing base and clearer regulatory milestones, while persistent enrollment and manufacturing challenges continued to cloud timelines. Early calls highlighted fast‑track designation for BX004, a delayed Part 2 readout and a looming going‑concern question. The APT acquisition in late‑2023 injected $50 million, extended runway to Q4 2025 and introduced BX211, but integration and shareholder approval risks surfaced. By 2024 the company reported orphan‑drug status for BX004, completed merger integration and secured a reverse split, yet manufacturing scale‑up for the Phase 2b CF trial caused a shift from an on‑track to a delayed schedule. 2025 brought positive Phase 2 data for BX211, additional $12 million financing and the start of BX004 Phase 2b dosing, but new regulatory hurdles (clinical hold on a nebulizer device) and ongoing cash‑runway limits re‑emerged. Overall, financing and regulatory approvals have improved, but enrollment, manufacturing and cash‑runway concerns remain recurring themes.

## Latest CallCard · Q3

BiomX advances BX004 Phase IIb (CF) despite FDA clinical hold on nebulizer; European enrollment continues. BX004 Q1 2026 readout on track. BX011 for diabetic foot infections gets positive FDA feedback with clear BLA pathway; DHA partnership supports dual-use potential. Cash runway into Q1 2026.

**Guidance:** vague — Cash runway into Q1 2026; BX004 Phase IIb data readout targeted Q1 2026; BX011 advancement contingent on financing and DHA alignment.

**Tone:** mgmt 0.3 · Q&A pressure 0.4 · divergence 0.2

Management highlights constructive FDA feedback on both programs, European enrollment progress, clear regulatory pathways, and growing phage therapy validation, while acknowledging the clinical hold as a technical challenge.

### Demand visibility

High unmet need recognized by FDA for both indications; strong patient enrollment interest in BX004; large addressable DFI population with no new approvals in 20+ years.

BX004: FDA acknowledges substantial unmet need in CF Pseudomonas infections despite CFTR modulators; European enrollment progressing beyond expectations. BX011: ~160,000 lower limb amputations annually in U.S. diabetic patients, 85% from DFI/osteomyelitis; established FDA guidance for DFI development.

### Margins / costs

Pre-revenue; operating expenses reduced year-over-year via workforce reduction, lower rent, and decreased CF manufacturing costs; cash burn remains significant.

Q3 2025 R&D $6.1M vs $7.3M prior year (lower salary, rent, CF manufacturing). G&A $2.4M vs $3.2M (lower salary, share-based comp, legal). Net cash used in operations $22M for 9 months ended Sept 2025 vs $30.7M prior year. Cash $8.1M at Sept 30, 2025.

### Capital allocation

Focused on advancing BX004 and BX011 clinical programs; leveraging DHA non-dilutive funding ($40M to date); seeking additional financing for BX011.

Cash used primarily for operating activities. DHA has provided $40M to date and may continue support. BX011 advancement explicitly subject to securing necessary financial resources. No dividends, buybacks, or M&A mentioned.

### Milestones

- **BX004 Phase IIb trial (CF)** [on_track]: First patient dosed; FDA clinical hold on U.S. sites due to nebulizer; European enrollment continues uninterrupted; Q1 2026 data readout targeted.
- **BX004 FDA written feedback** [delivered]: FDA acknowledges unmet need, outlines Phase III pathways including enrichment strategies (e.g., non-CFTR modulator patients, bronchiectasis).
- **BX011 DFI program** [new]: Positive FDA feedback on BLA pathway; no additional nonclinical studies requested; CMC comments aligned; off-the-shelf formulation for outpatient use; DHA dual-use potential for combat wounds.
- **BX011 Phase II trial planning** [on_track]: Aligning study design with DHA; fine-tuning endpoints per FDA guidance; no animal safety or skin penetration studies required.
- **Cash runway** [on_track]: Cash, equivalents, and restricted cash sufficient to fund operations into Q1 2026.

### Fears / risks

- **Regulatory**: FDA clinical hold on BX004 U.S. sites could delay enrollment and data readout if not lifted imminently.
- **Financial**: Cash runway only into Q1 2026; BX011 advancement subject to securing additional financial resources.
- **Clinical**: BX004 Phase IIb readout dependent on hold resolution and enrollment completion in both U.S. and Europe.
- **Manufacturing/Device**: Nebulizer device technical issues causing clinical hold despite CE marking in Europe.
- **Competition**: Growing phage therapy field validation may increase competition for partnerships and funding.
- **Partnership**: BX011 progress dependent on continued DHA funding and potential pharma partnerships.

### Key quotes

> “We began the quarter strongly with first patient dosing in our Phase IIb trial, a significant milestone in the development of this innovative phage therapy.”

> “This hold relates solely to third-party nebulizer device used to deliver BX004, not to a drug candidate itself. Importantly, the FDA raised no concern about BX004 in their notification.”

> “BiomX estimates its cash, cash equivalents and restricted cash are sufficient to fund its operations into the first quarter of 2026.”

## Quarter one-liners

- **2025 Q3:** BiomX advances BX004 Phase IIb (CF) despite FDA clinical hold on nebulizer; European enrollment continues. BX004 Q1 2026 readout on track. BX011 for diabetic foot infections gets positive FDA feedback with clear BLA pathway; DHA partnership supports dual-use potential. Cash runway into Q1 2026.
- **2025 Q2:** BiomX reports successful start of BX004 Phase IIb dosing, published BX004 data, strong BX211 Phase II results, and cash sufficient into Q1 2026, while seeking FDA feedback on real‑world evidence and planning a BX211 registrational study.
- **2025 Q1:** BiomX reports positive Phase 2 BX211 data in DFO, $12M financing extends cash runway to Q1 2026 ahead of BX004 CF Phase 2b readout.
- **2024 Q3:** BiomX completed BX211 Phase 2 DFO enrollment with top-line data expected Q1 2025; BX004 Phase 2b delayed to H1 2026 due to manufacturing scale-up; cash runway into Q4 2025.
- **2024 Q2:** BiomX Q2 2024 call highlighted strong cash position, progress on BX004 and BX211 trials, completed merger integration, and maintained guidance through Q4 2025 despite enrollment and outcome uncertainties.
- **2024 Q1:** BiomX closed APT merger and $50M financing in March 2024, advancing two Phase II phage programs (BX004 for CF, BX211 for DFO) with cash runway through Q4 2025; key milestones: BX211 Week 13 data Q1 2025, BX004 Phase IIb top-line Q3 2025, FDA Type C meeting mid-2024; going concern doubt flagged over 
- **2023 Q4:** BiomX completed APT acquisition, raised $50M, advancing two Phase II phage programs (BX004 for CF, BX211 for DFO) with 2025 data readouts; cash runway 12+ months but going concern doubt pending shareholder approval.
- **2023 Q2:** BiomX completed Part 2 screening for BX004 CF trial with enrollment exceeding expectations, received FDA Fast Track designation, but top-line data delayed to November; cash runway into Q3 2024.

## Theme arcs

- **Cash runway and financing** (improving): Series of PIPEs, private placement and $12M financing extended runway from Q3 2024 to Q1 2026
- **Regulatory uncertainty** (stable): Fast‑track, orphan designation and multiple FDA meetings achieved, but holds and feedback remain unpredictable
- **Clinical trial enrollment** (deteriorating): Consistent enrollment difficulty for BX004 and patient‑specific BX211 trials
- **Manufacturing scale‑up** (deteriorating): Scale‑up from 10L to 50L delayed BX004 Phase 2b readout to H1 2026
- **Going‑concern risk** (improving): Financing mitigated but doubt persists due to conversion of preferred stock
- **Corporate integration** (resolved): APT merger integration completed by Q2 2024
- **Pipeline expansion** (new): Introduction of BX211 and BX011 programs after 2023
- **Strategic partnership reliance** (new): Dependence on Defense Health Agency and potential partners noted in 2025

## Guidance path

2023 Q2:vague → 2023 Q4:vague → 2024 Q1:vague → 2024 Q2:maintained → 2024 Q3:vague → 2025 Q1:maintained → 2025 Q2:maintained → 2025 Q3:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/PHGE`